| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_84d9adaa7e7ce01ce8020f5c721aba10 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2866 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-146
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-425
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2027
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2009
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2013
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2077
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2866 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-425
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-20 |
| filingDate |
2004-08-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e6ed9c0bdf82190c45a713b6f8f17356
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_494f05b6de3bfae21f9f51f126dbceac
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_87509fd56ee430732dc3c029c9e48872
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4113a3a00c4ba974a2ec23f71f9aefe9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9fbb25b1e0b539466a705d1169232b7b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e3d968cb40c1a4c9a1678237ae4d81dd
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f64f5ee30a58d6524377738af116c20a |
| publicationDate |
2011-11-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
KR-20110122771-A |
| titleOfInvention |
Pharmaceutical solid dosage forms comprising HIV protease inhibitor solid dispersion |
| abstract |
Pharmaceutical solid formulations have been described that provide improved oral bioavailability for HIV protease inhibitors. In particular, the formulation comprises at least one HIV protease inhibitor and at least one pharmaceutically acceptable water soluble polymer and a solid dispersion of at least one pharmaceutically acceptable surfactant, wherein the pharmaceutically acceptable water soluble polymer is about 50 ° C. It has more than Tg. Preferably, the pharmaceutically acceptable surfactant has an HLB value of about 4 to about 10. |
| priorityDate |
2003-08-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |